*Sponsored
Market Crux Announces Hoth Therapeutics, Inc. (NASDAQ: HOTH) Will Be Topping Its Watchlist Tomorrow Morning—Tuesday, September 2, 2025
And Here's Why We'll Have All Eyes On It…
Analyst Coverage: Jason Kolbert Of D. Boral Capital Recently Reiterated A $5 Target On (HOTH), Highlighting More Than 300% Potential Upside From Recent Levels.
Small Float: According To MarketWatch, (HOTH) Has Fewer Than 14M Shares In Its Public Float, Which Could Set The Stage For Big Moves If Demand Begins To Shift.
Recent Momentum: (HOTH) Made An Approximate 114% Move In Just A Few Sessions, From Around $0.83 To $1.78.
Technical Setup: (HOTH) Is Currently Trending Near Or Above All Major Moving Averages Tracked By Barchart, Including Its 5-, 20-, 50-, 100-, And 200-Day Lines.
Pull Up (HOTH) Before Tomorrow Morning September 1, 2025
Right Before Bed | See Why (NASDAQ: HOTH) Will Be Topping Our Watchlist Tomorrow Dear Reader, Hope your long weekend was a good one—because the week ahead is already shaping up to be a big one on our radar. Tomorrow morning could bring a biotech story straight to the front of the watchlist. That's why, on Tuesday, September 2, 2025, we'll have all eyes on Hoth Therapeutics, Inc. (NASDAQ: HOTH) as our next potential breakout idea. Now that the spotlight is on, here's why this name stands out from the rest. According to MarketWatch, (HOTH) has fewer than 14M shares listed in its public float. With floats this small, there's the potential for big moves if demand starts to shift—and history shows exactly how quickly that can play out. Looking back at early June, (HOTH) made an approximate 114% move in just a few sessions, from around $0.83 on June 2 to $1.78 by June 5, according to Barchart. Today, (HOTH) is trending near or above every major moving average tracked by Barchart—including its 5-, 20-, 50-, 100-, and 200-day lines—a technical setup that keeps the potential for continued momentum firmly in focus. Adding fuel to the story, biotech analyst Jason Kolbert of D. Boral Capital recently reiterated his $5 target on (HOTH), framing a potential upside of more than 300% from recent levels. Multiple news sites and market portals, including Benzinga, GuruFocus, and MarketWatch have reported that D. Boral Capital analyst Jason Kolbert recently reiterated a $5 target on (HOTH), which suggests over 300% upside potential from its recent levels. 
But the chart and analyst coverage are only part of the story. What makes (HOTH) especially compelling is what's happening inside the company itself. A Broad Approach to Innovation
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company built on one clear mission: develop innovative treatments that make life better for people facing serious conditions. What sets (HOTH) apart is its broad approach. Rather than focusing on a single therapy, the company is advancing a portfolio of programs across cancer, Alzheimer's, eczema, asthma, and—most recently—metabolic disease through a U.S. Department of Veterans Affairs (VA)–licensed program targeting obesity and fatty liver. This isn't about one shot at success—it's a coordinated push across several of the highest-impact areas in medicine today. Each program addresses a different challenge, but together they tell the story of a company determined to bring impactful breakthroughs to patients who need them. What Hoth Is Working On
(HOTH) isn't built on just one program—it's advancing a lineup aimed at some of medicine's toughest challenges. The lead candidate, HT-001, targets the painful rashes and hair loss caused by EGFR inhibitors. With no approved treatment for these side effects, the need is clear. Early studies showed HT-001 cut reactions by more than half, and a mid-stage trial is now enrolling across the U.S. Beyond that, HT-KIT is designed for rare cancers driven by genetic mutations. By targeting the mutations directly, preclinical data suggests it could succeed where other therapies fall short. In neurology, HT-ALZ focuses on Alzheimer's by addressing a brain pathway tied to inflammation and memory. Early results point to potential improvements in learning and recall. Dermatology is also in focus with BioLexa, a non-steroid lotion for eczema flare-ups that disrupts the bacteria driving them, offering a possible safer alternative to steroids. With HT-004, Hoth is taking on asthma by aiming to calm lung inflammation in ways current treatments often miss. And most recently, Hoth expanded into metabolic disease with a VA-licensed program centered on GDNF, a biologic that has already shown effects on metabolism in preclinical studies. Together, these programs highlight how (HOTH) isn't built on a single path forward, but on a diverse pipeline spanning oncology, neurology, dermatology, and inflammatory disease. Here's a closer look at where each program stands today: 
Recent Developments
The summer of 2025 has been a turning point for (HOTH), marked by data readouts, new partnerships, and trial expansions that push its pipeline further into the spotlight. In late June, interim results from the HT-001 Phase 2a trial added fresh momentum. Every patient in the open-label group achieved at least one primary measure of improvement, while more than 65% reported relief from pain and itching. Perhaps most importantly, none of the participants had to reduce or stop their cancer therapy due to skin side effects—a clear sign that HT-001 could improve quality of life without disrupting treatment. That same week, (HOTH) took a decisive step into metabolic disease by announcing a joint venture to develop a therapy licensed from the U.S. Department of Veterans Affairs (VA). The program centers on GDNF, a biologic with strong preclinical evidence for regulating metabolism and reducing weight. Momentum carried into July with a formal CRADA collaboration with the VA and the Foundation for Atlanta Veterans Education and Research (FAVER). This study will benchmark GDNF against semaglutide—the current standard in obesity care—through advanced translational models. By running this head-to-head design, Hoth is positioning itself to generate data that could spark real attention across the broader healthcare landscape. Closing out the month, (HOTH) announced a partnership with ICON Clinical Research to expand the HT-001 Phase II trial into Europe. Approvals in multiple EU countries are anticipated, setting the stage for faster patient enrollment and laying the groundwork for a potential global Phase III study. Together, these updates show a company not just building a pipeline—but actively advancing programs that could impact cancer care, metabolic disease, and beyond. And with all of this potential momentum converging right now, here's why (HOTH) will be at the very top of our watchlist heading into tomorrow's session. 7 Reasons Why (HOTH) Will Be Topping Our Watchlist Tomorrow Morning —Tuesday, September 2, 2025…
1. Analyst Target: Jason Kolbert of D. Boral Capital recently reiterated a $5 target on (HOTH), suggesting more than 300% potential upside from its recent levels. 2. Small Float: according to MarketWatch, (HOTH) has fewer than 14M shares in its public float, which could lead to the potential for big moves if demand begins to shift. 3. Recent Momentum: in early June, (HOTH) moved approximately 114% in just a few sessions, moving from around $0.83 to $1.78, showing how quickly momentum can build. 4. Strong Technicals: today, (HOTH) is trending near or above all major moving averages tracked by Barchart, including its 5-, 20-, 50-, 100-, and 200-day lines. 5. Pipeline Depth: (HOTH) is advancing multiple programs across cancer, Alzheimer's, eczema, asthma, and metabolic disease—offering more than one path for potential progress. 6. Fresh Data: interim results from the Phase 2a trial of (HOTH)'s lead candidate HT-001 showed consistent improvement across key measures, while patients were able to stay on their cancer therapies. 7. Global Expansion: (HOTH) recently partnered with ICON Clinical Research to expand its HT-001 trial into Europe, paving the way for faster enrollment and a potential global Phase III study. 
Pull Up (HOTH) Before Tomorrow Morning
Company Website | Corporate Presentation
With fewer than 14M shares in its float, according to MarketWatch, (HOTH) has already shown how quickly momentum can build—moving approximately 114% in just a few sessions back in June. Today, it's trending near or above every major moving average tracked by Barchart, supported by fresh Phase 2a data from HT-001 and an ongoing expansion into Europe through a partnership with ICON Clinical Research. Layer on a diverse pipeline spanning cancer, Alzheimer's, eczema, asthma, and metabolic disease—plus analyst coverage reaffirming a $5 target—and you can see why this name has landed squarely on our radar. We will have all eyes on (HOTH) tomorrow morning. Take a look at (HOTH) before you call it a night. Also, keep a lookout for my morning update. Have a good night. Sincerely,
Gary Silver
Managing Editor,
Market Crux
| 
